Robert F Kennedy Jr leaves US vaccine guidance stalled after dismantling advisory panel

Access to newly authorized vaccines across the United States has stalled following sweeping policy shifts directed by Health and Human Services Secretary Robert F. Kennedy Jr., according to a report from The Guardian. The disruptions have left federal immunization guidance paralyzed, leaving patients facing unexpected out-of-pocket expenses and widespread coverage uncertainty.

The turmoil stems from Kennedy’s efforts to overhaul federal vaccination standards, which included reducing childhood immunization recommendations by a third and replacing established experts on the Advisory Committee on Immunization Practices with his own chosen allies. A judicial ruling subsequently halted those changes on procedural grounds, effectively dismantling the panel. However, Kennedy has since refrained from properly appointing new committee members, leaving the influential advisory body entirely inactive even as the Food and Drug Administration approves new inoculations.

Under federal rules, private health insurers are not obligated to provide full coverage for newly cleared vaccines until after the panel issues formal recommendations. When the advisory group endorses a shot, insurers generally receive a window of at least a year to incorporate coverage into upcoming benefit plans, which typically begin in January. Because the committee is currently non-operational, public health specialists warn that required coverage for recently approved vaccines could be postponed until 2029 or beyond.

The fallout is already creating direct hurdles for consumers. Ron Kroening, a retired state immunization worker in Oklahoma who has asthma, encountered unexpected out-of-pocket costs when attempting to receive a newly approved mRNA flu vaccine cleared by regulators for adults aged 50 and older. After finding a pharmacy stocking the shot, he was charged a $40 co-pay because his health plan does not fully cover the product in the absence of an official committee recommendation.

Public health analysts stress that financial outlays and logistical barriers quickly depress uptake. The paralysis also extends into other areas of healthcare delivery. Certain states bar pharmacists from administering doses lacking federal committee endorsements. Furthermore, earlier panel votes that were ultimately voided by the court action, including an effort to end universal newborn hepatitis B vaccinations, continue to cause friction across state legislatures. Delays in coverage have likewise been reported for senior flu immunizations under Medicare, where payment is legally mandated regardless of the panel's actions.

Legal and health policy specialists note that the federal administration has demonstrated little urgency in rebuilding the advisory group through lawful avenues. While government attorneys appealed the court order that dissolved the earlier slate of appointees, critics suggest the prolonged absence of a functioning body enables officials to bypass standard administrative review while attempting to reshape vaccine guidelines. Experts warn that even if litigation ends, the panel's historic independence has suffered severe damage that could require congressional legislation to repair.